

<b>Reference:</b>	FOI.6745.21
<b>Subject:</b>	Treatment of schizophrenia
<b>Date of Request:</b>	23 August 2021

**Requested:**

I am writing to you today to request information relating to the treatment of schizophrenia by your trust

1. In the past 6 months, how many patients has your trust treated [for any condition] with the following drugs:
  - Aripiprazole long-acting injectable (Abilify Maintena)
  - Olanzapine pamoate (Zypadhera)
  - Paliperidone palmitate, once monthly (Xeplion)
  - Paliperidone palmitate, three monthly (Trevicta)
  - Risperidone long-acting injectable (Risperdal Consta)
  - Flupentixol decanoate (Depixol)
  - Fluphenazine decanoate (Modecate)
  - Haloperidol decanoate (Haldol Decanoate)
  - Pipotiazine palmitate (Piportil)
  - Zuclopenthixol decanoate (Clopixol)
2. Within your organisation how many patients are currently [within the past 6 months] being treated for Schizophrenia (ICD code: F20)
3. Of the Schizophrenia patients ONLY, how many are currently [within the past 6 months] being treated with the following drugs:
  - Aripiprazole long-acting injectable (Abilify Maintena)
  - Olanzapine pamoate (Zypadhera)
  - Paliperidone palmitate, once monthly (Xeplion)
  - Paliperidone palmitate, three monthly (Trevicta)
  - Risperidone long-acting injectable (Risperdal Consta)
  - Flupentixol decanoate (Depixol)
  - Fluphenazine decanoate (Modecate)
  - Haloperidol decanoate (Haldol Decanoate)
  - Pipotiazine palmitate (Piportil)
  - Zuclopenthixol decanoate (Clopixol)

**Response:**

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested for question 3, as it is estimated that the cost of answering your request would exceed the "appropriate limit" as stated in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. The "appropriate limit" represents the estimated cost of one person spending 18 hours (or 2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to respond to this request, the UHB would need to undertake a manual trawl of patient records and cross reference with the Pharmacy system, to identify what is requested, as the information is not recorded centrally.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under section 16 of the FoIA, we are required, as a public authority, to provide advice and assistance so far as it is reasonable, to individuals who have made a request under FoIA. Therefore, the UHB provides the information for questions 1 and 2 below.

1. The UHB provides, within the table overleaf, the number of patients treated, with the listed medications, during the period 1 March to 31 August 2021.

Medication	Number of patients
Aripiprazole long-acting injectable (Abilify Maintena)	136
Olanzapine pamoate (Zypadhera)	8
Paliperidone palmitate, once monthly (Xeplion)	96
Paliperidone palmitate, three monthly (Trevicta)	7
Risperidone long-acting injectable (Risperdal Consta)	22
Flupentixol decanoate (Depixol)	6
Fluphenazine decanoate (Modecate)	0
Haloperidol decanoate (Haldol Decanoate)	*
Pipotiazine palmitate (Piportil)	0
Zuclopenthixol decanoate (Clopixol)	8

Where the figure in the table has been replaced with an asterisk (\*), the UHB is unable to provide you with the exact number of patients, due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018/General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 define personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.

2. The UHB confirms that eighty seven (87) patients have been admitted and treated for Schizophrenia who were coded as F20 on the UHB's Welsh Patient Administration system, during the period 1 March 2021 to 31 August 2021.

Please note: Recent figures may be subject to change because of a standard clinical coding backlog of up to three (3) months.